ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Bayer, BioNTech and Sanofi side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

Bayer×BioNTech×Sanofi×Three at a time for now; Pro will compare up to ten.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

BayerBioNTechSanofi
studies on the registry1,6941242,424
open to participants now6033104
phase 3 studies under way11961
reach primary completion within a year351165
programswith a study of their own in two years212380+12 named only

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phaseBayerBioNTechSanofi
Phase 119%

BioNTech: 4 of its 23 programs at phase 1

  1. BNT168phase 1
  2. BNT3219phase 1
  3. BNT351phase 1
  4. CV09070101phase 1
17%
28%
Phase 2

Bayer: 8 of its 21 programs at phase 2

  1. AB-1005phase 2
  2. WRN Inhibitor RO7589831phase 2
  3. nurandociguatphase 2
  4. BAY 3401016phase 2
  5. BAY 3670549phase 2

and 3 more — sign in to see them all

38%
65%

Sanofi: 25 of its 80 programs at phase 2

  1. brivekimigphase 2
  2. Acne mRNA vaccinephase 2
  3. Daxokafusp Alfaphase 2
  4. RSV+HMPV vaccinephase 2
  5. BLU-808phase 2

and 20 more — sign in to see them all

31%
Phase 3

Bayer: 4 of its 21 programs at phase 3

  1. elinzanetantphase 3
  2. sevabertinibphase 3
  3. bemdaneprocelphase 3
  4. aficamtenphase 3
19%

BioNTech: 3 of its 23 programs at phase 3

  1. pumitamigphase 3
  2. Elfetabart Drozuntecanphase 3
  3. trastuzumab pamirtecanphase 3
13%

Sanofi: 22 of its 80 programs at phase 3

  1. rilzabrutinibphase 3
  2. frexalimabphase 3
  3. Pneumococcal 21-Valent Conjugate Vaccinephase 3
  4. lunsekimigphase 3
  5. duvakitugphase 3

and 17 more — sign in to see them all

28%
Approved, new studies

Bayer: 5 of its 21 programs at approved, new studies

  1. finerenoneapproved, new study
  2. darolutamideapproved, new study
  3. Aspirinapproved, new study
  4. acoramidisapproved, new study
  5. Levonorgestrelapproved, new study
24%

BioNTech: 1 of its 23 programs at approved, new studies

  1. BNT162 Vaccineapproved, new study
4%

Sanofi: 11 of its 80 programs at approved, new studies

  1. dupilumabapproved, new study
  2. belumosudilapproved, new study
  3. sarilumabapproved, new study
  4. fitusiranapproved, new study
  5. Avapritinibapproved, new study

and 6 more — sign in to see them all

14%

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
Bayer10 readouts · 4 phase 3·

Bayer, Dec ’26: 1 program whose next study reaches primary completion

  1. BAY 3389934phase 1 · Dec 25 · NCT06854640

Bayer, Jan ’27: 1 program whose next study reaches primary completion

  1. elinzanetantphase 3 · Jan 22 · NCT07762287
·

Bayer, Mar ’27: 1 program whose next study reaches primary completion

  1. Aspirinapproved, new study · Mar 10 · NCT07652723

Bayer, Apr ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. finerenoneapproved, new study · Apr 10 · NCT05196035

Bayer, May ’27: 2 programs whose next study reaches primary completion

  1. nurandociguatphase 2 · May 7 · NCT07431294
  2. WRN Inhibitor RO7589831phase 2 · May 31 · NCT06004245
·

Bayer, Jul ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. darolutamideapproved, new study · Jul 30 · NCT05794906

Bayer, Aug ’27: 1 program whose next study reaches primary completion

  1. RAS/PI3K-alpha Inhibitor VVD-159642phase 1 · Aug 1 · NCT06804824

Bayer, Sep ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. acoramidisapproved, new study · Sep 17 · NCT07298044

Bayer, Oct ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. sevabertinibphase 3 · Oct 28 · NCT06452277
BioNTech4 readouts · 1 phase 3

BioNTech, Nov ’26: 1 program whose next study reaches primary completion

  1. BNT351phase 1 · Nov 0 · NCT07392372
·

BioNTech, Jan ’27: 1 program whose next study reaches primary completion

  1. pumitamigphase 3 · Jan 1 · NCT05879055
··

BioNTech, Apr ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. BNT162 Vaccineapproved, new study · Apr 21 · NCT07798648
·

BioNTech, Jun ’27: 1 program whose next study reaches primary completion

  1. BNT166Aphase 2 · Jun 0 · NCT07379580
····
Sanofi29 readouts · 10 phase 3

Sanofi, Nov ’26: 3 programs whose next study reaches primary completion, 3 in phase 3

  1. rilzabrutinibphase 3 · Nov 25 · NCT07216079
  2. NVX-CoV2373 adjuvated lipid nanoparticleapproved, new study · Nov 26 · NCT07861542
  3. Measles, combinations with mumps and rubella, live attenuatedphase 3 · Nov 28 · NCT07103148

Sanofi, Dec ’26: 5 programs whose next study reaches primary completion, 1 in phase 3

  1. Pandemic flu H5 HA mRNA SD2 vaccinephase 2 · Dec 1 · NCT06907511
  2. Pneumococcal 21-Valent Conjugate Vaccinephase 3 · Dec 1 · NCT06838000
  3. brivekimigphase 2 · Dec 17 · NCT06958536
  4. frexalimabphase 3 · Dec 23 · NCT06500702
  5. BLU-808phase 2 · Dec 31 · NCT06931405

Sanofi, Jan ’27: 5 programs whose next study reaches primary completion, 1 in phase 3

  1. efanesoctocog alfaapproved, new study · Jan 15 · NCT04644575
  2. RSV+HMPV vaccinephase 2 · Jan 18 · NCT06686654
  3. Daxokafusp Alfaphase 2 · Jan 19 · NCT05584670
  4. belumosudilapproved, new study · Jan 26 · NCT07726914
  5. rF1V-1018phase 2 · Jan 29 · NCT07207408

Sanofi, Feb ’27: 2 programs whose next study reaches primary completion, 2 in phase 3

  1. dupilumabapproved, new study · Feb 7 · NCT07905547
  2. itepekimabphase 3 · Feb 17 · NCT07424144

Sanofi, Mar ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. fitusiranapproved, new study · Mar 25 · NCT05662319

Sanofi, Apr ’27: 6 programs whose next study reaches primary completion

  1. H5 Flu IMP 2phase 1 · Apr 4 · NCT07516418
  2. Inosine Monophosphatephase 1 · Apr 4 · NCT07516418
  3. RSV IMP 4phase 1 · Apr 4 · NCT07516418
  4. RSV IMP 5phase 1 · Apr 4 · NCT07516418
  5. RSV IMP 6phase 1 · Apr 4 · NCT07516418

and 1 more — sign in to see them all

Sanofi, May ’27: 1 program whose next study reaches primary completion

  1. SAR402663phase 2 · May 18 · NCT06660667

Sanofi, Jun ’27: 2 programs whose next study reaches primary completion

  1. lunsekimigphase 3 · Jun 21 · NCT06676319
  2. Avapritinibapproved, new study · Jun 23 · NCT03731260

Sanofi, Jul ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. riliprubartphase 3 · Jul 9 · NCT06290141
·

Sanofi, Sep ’27: 2 programs whose next study reaches primary completion, 1 in phase 3

  1. zetrukibartphase 2 · Sep 22 · NCT07225569
  2. amlitelimabphase 3 · Sep 30 · NCT06241118

Sanofi, Oct ’27: 1 program whose next study reaches primary completion

  1. SAR446597phase 2 · Oct 13 · NCT07215234
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 20, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

Bayer

New programs 0

None

Reached a new phase 1

Study stopped 0

None

Primary completion later 2

BioNTech

New programs 2

  • BNT3219phase 1 · first study · Oct 19
  • BNT3210phase 2 · first study · Oct 15

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 2

Sanofi

New programs 5

Reached a new phase 1

Study stopped 4

  • balinatunfibphase 2 · terminated Oct 22 · none of its studies left running“Business decision” · NCT07222189
  • balinatunfibphase 2 · terminated Oct 21 · none of its studies left running“Business decision” · NCT06867094
  • balinatunfibphase 2 · terminated Oct 13 · none of its studies left running“Business decision.” · NCT06637631
  • amlitelimabphase 2 · terminated Oct 2“Sponsor decision; the decision is not related to any safety concern.” · NCT06033833

Primary completion later 2

Where they overlap

Conditions where at least two of them have programs: 11 in all. A program counts in each condition its studies name most.

ConditionBayerBioNTechSanofi
Carcinoma, Non-Small-Cell Lungall three · compare here

Bayer in Carcinoma, Non-Small-Cell Lung: 2 programs

  1. sevabertinibphase 3
  2. PRMT5 Inhibitor BAY 3713372phase 2

Their studies: Bayer’s studies of Carcinoma, Non-Small-Cell Lung in search

BioNTech in Carcinoma, Non-Small-Cell Lung: 2 programs

  1. pumitamigphase 3
  2. beruzatatug pelitecanphase 2

Their studies: BioNTech’s studies of Carcinoma, Non-Small-Cell Lung in search

Sanofi in Carcinoma, Non-Small-Cell Lung: 2 programs

  1. Tadalafilphase 3
  2. Pan-KRAS Inhibitor BLU-924phase 2

Their studies: Sanofi’s studies of Carcinoma, Non-Small-Cell Lung in search

Colorectal Neoplasmsall three · compare here

Bayer in Colorectal Neoplasms: 2 programs

  1. sevabertinibphase 3
  2. WRN Inhibitor RO7589831phase 2

Their studies: Bayer’s studies of Colorectal Neoplasms in search

Sanofi in Colorectal Neoplasms: 1 program

  1. tusamitamab sonditecanphase 1

Their studies: Sanofi’s studies of Colorectal Neoplasms in search

Influenza, Human2 of 3 · compare here–
COVID-192 of 3 · compare here–

BioNTech in COVID-19: 1 program

  1. BNT162 Vaccineapproved, new study

Their studies: BioNTech’s studies of COVID-19 in search

Sanofi in COVID-19: 3 programs

  1. NVX-COV2705phase 3
  2. Biological Productsphase 1
  3. NVX-CoV2373 adjuvated lipid nanoparticleapproved, new study

Their studies: Sanofi’s studies of COVID-19 in search

Carcinoma, Renal Cell2 of 3 · compare here–

Sanofi in Carcinoma, Renal Cell: 1 program

  1. Biological Productsphase 1

Their studies: Sanofi’s studies of Carcinoma, Renal Cell in search

Diabetes Mellitus, Type 22 of 3 · compare here

Bayer in Diabetes Mellitus, Type 2: 2 programs

  1. finerenoneapproved, new study
  2. Levonorgestrelapproved, new study

Their studies: Bayer’s studies of Diabetes Mellitus, Type 2 in search

–

Sanofi in Diabetes Mellitus, Type 2: 1 program

  1. iGlarLixi (insulin glargine/lixisenatide)approved, new study

Their studies: Sanofi’s studies of Diabetes Mellitus, Type 2 in search

Parkinson Disease2 of 3 · compare here

Bayer in Parkinson Disease: 2 programs

  1. bemdaneprocelphase 3
  2. AB-1005phase 2

Their studies: Bayer’s studies of Parkinson Disease in search

–

Sanofi in Parkinson Disease: 1 program

  1. Biological Productsphase 1

Their studies: Sanofi’s studies of Parkinson Disease in search

Pneumococcal Infections2 of 3 · compare here–

BioNTech in Pneumococcal Infections: 1 program

  1. BNT162 Vaccineapproved, new study

Their studies: BioNTech’s studies of Pneumococcal Infections in search

Carcinoma, Hepatocellular2 of 3 · compare here

BioNTech in Carcinoma, Hepatocellular: 1 program

  1. pumitamigphase 3

Their studies: BioNTech’s studies of Carcinoma, Hepatocellular in search

–
Neoplasm Metastasis2 of 3 · compare here

Bayer in Neoplasm Metastasis: 1 program

  1. darolutamideapproved, new study

Their studies: Bayer’s studies of Neoplasm Metastasis in search

BioNTech in Neoplasm Metastasis: 1 program

  1. trastuzumab pamirtecanphase 3

Their studies: BioNTech’s studies of Neoplasm Metastasis in search

–
Prostatic Neoplasms2 of 3 · compare here

Bayer in Prostatic Neoplasms: 1 program

  1. darolutamideapproved, new study

Their studies: Bayer’s studies of Prostatic Neoplasms in search

BioNTech in Prostatic Neoplasms: 1 program

  1. Elfetabart Drozuntecanphase 3

Their studies: BioNTech’s studies of Prostatic Neoplasms in search

–

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

A target, or a pathogen for a vaccine, known for: Bayer 13 of 21 · BioNTech 11 of 23 · Sanofi 54 of 80 programs (29 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.
  • Programs a company names but has not registered are counted apart (Sanofi: 12).